Research programme: glycosylated taxoid derivatives - KakenAlternative Names: Glycosylated taxoid derivatives research programme - Kaken
Latest Information Update: 22 Mar 2007
At a glance
- Originator Kaken Pharmaceutical
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jul 1999 This programme is available for licensing (http://www.kaken.co.jp)
- 23 Jul 1999 Preclinical development for Cancer in Japan (unspecified route)